J&J buys another medtech company in $13.1B Shockwave deal

John­son & John­son’s ac­qui­si­tion strat­e­gy has large­ly fo­cused on med­ical tech­nol­o­gy com­pa­nies in the past few years, as the health­care gi­ant splash­es an­oth­er $13.1 bil­lion in cash to buy Shock­wave Med­ical.

The Fri­day morn­ing deal adds to the New Jer­sey-based con­glom­er­ate’s car­dio­vas­cu­lar in­ter­ven­tions fol­low­ing a $400 mil­lion buy­out of Lam­i­nar last No­vem­ber and $16.6 bil­lion takeover of Abio­med in No­vem­ber 2022. On the phar­ma­ceu­ti­cals front, J&J has inked mul­ti­ple R&D and li­cens­ing pacts but few­er ac­qui­si­tions, with Jan­u­ary’s $2 bil­lion move for ADC drug­mak­er Am­brx Bio­phar­ma as one of its on­ly such deals in re­cent years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.